CAMBRIDGE, Mass. — January 8, 2026 — Leads & Copy — Flare Therapeutics Inc. (FlareTx), a clinical-stage biotechnology company, announced that CEO Doug Manion, M.D., FRCP (C), will present a company overview at the 44th Annual J.P. Morgan Healthcare Conference on January 15, 2026, at 8:00 a.m. PT in San Francisco, CA.
Flare Therapeutics focuses on drugging transcription factors to unlock the therapeutic potential of this target class. Their lead program, FX-909, is an orally available small molecule inhibitor of PPARG, the master regulator of the luminal lineage, being developed for locally advanced or metastatic urothelial cancer. FX-909 has achieved clinical proof-of-concept in a Phase 1A study as a monotherapy and is actively dosing patients in a Phase 1B study to determine the recommended Phase 2 dose in a biomarker-defined population.
The second lead program, FX-111, is a novel and highly differentiated potent and selective degrader for ARON, the transcriptionally active, hormone-bound androgen receptor. This approach aims to overcome key vulnerabilities of conventional therapies targeting AROFF and has broad potential across prostate cancer at all stages. FX-111 is undergoing Investigational New Drug (IND)-enabling studies for initial development for the treatment of metastatic castration-resistant prostate cancer (mCRPC).
These two programs, along with an earlier-stage portfolio targeting transcription factors involved in oncology and other therapeutic areas, leverages Flare Therapeutics’ integrated discovery platform of capabilities that identifies novel validated ligands to the undrugged proteome.
Contacts:
Investors:
Sarah McCabe
investorrelations@flaretx.com
Media:
Timothy Cockroft
media@flaretx.com
Source: Flare Therapeutics Inc.
